Although not specific to liver cancer cells (as in the previous post) this modified type 2 herpes simplex virus,HSV-2, called FusOn-H2 is effective against in vivo primary & metastatic breast tumors by selectively replicating in cancer cells (& thus killing them) as well as activating the immune system
http://www.ncbi.nlm.nih.gov/entrez/q...66169&query_hl
Induction of strong antitumor immunity by an HSV-2-based oncolytic virus in a murine mammary tumor model.
Threaded Mode